LBI-HTA - Publications - Search - Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin's lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL)

Hintringer, K. (2012): Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin's lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL). DSD: Horizon Scanning in Oncology 26.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
257Kb
Abstract

Brentuximab vedotin is an antibody-drug conjugate (ADC) directed against the tumour necrosis factor (TNF) receptor CD30 which is expressed on the surface of tumour cells in haematological malignancies including Hodgkin's lymphoma (HL) and anaplastic large cell lymphoma (ALCL). Brentuximab is indicated for the treatment or relapses or refractory HL after failure of at least two prior multi-agent chemotherapy regimens and for the treatment of relapsed systemic ALCL (sALCL) after at least one prior multi-agent chemotherapy regimen. In Europe, brentuximab is currently under marketing authorisation review for these two indications and in the US, it was approved in August 2011 for these two indications based on response rates observed in two single-arm phase II studies – one in HL (n=102) and one in sALCL (n=58). Overall, the response rates (75% and 86% in HL and sALCL, respectively) in both trials were considered as clinically relevant. Complete remissions were achieved by 34% and 57% in HL and sALCL patients, respectively. Duration of ORR was 6.7 months and 12.6 months in HL and sALCL patients, respectively. Overall, the small population included and the single-arm design, as well as the primary efficacy endpoint 'response rate' do not allow full characterisation of the safety and efficacy profile of brentuximab vedotin based on the available data.

Item Type:DSD: Horizon Scanning in Oncology
Keywords:brentuximab vedotin, brentuximab, adcetris, hodgkin's lymphoma, HL, anaplastic large cell lymphoma, ALCL
Subjects:WB Practice of medicine > WB 300-962 Therapeutics
WH Hemic and lymphatic systems
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
Language:English
Series Name:DSD: Horizon Scanning in Oncology 26
Deposited on:13 Jun 2012 13:03
Last Modified:13 Jun 2012 13:03

Repository Staff Only: item control page